Rho Capital Partners Inc Mersana Therapeutics, Inc. Transaction History

Rho Capital Partners Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	BUY	$4.63 - $8.0 $0 - $0	0 New	0 $0
Q2 2022 Aug 01, 2022	SELL	$2.84 - $5.0 $2.26 Million - $3.98 Million	-796,458 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$13.56 - $18.48 $292,557 - $398,706	-21,575 Reduced 2.64%	796,458 $12.6 Million
Q2 2017 Aug 07, 2017	BUY	N/A	818,033	818,033 $11.4 Million

130

104M

58.5K

471K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $56.4M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Rho Capital Partners Inc, based on Form 13F filings with the SEC.

Stay updated on Rho Capital Partners Inc with notifications on news.